Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.

Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.